TWST Stock Forecast & Price Target

Twist Bioscience is viewed positively because its proprietary silicon-based DNA synthesis platform meaningfully lowers cost and increases throughput versus traditional methods, creating a durable competitive advantage in a large and expanding synthetic biology market served by commercial diagnostic labs, biopharma research teams, and academic institutions. The thesis is further supported by accelerating AI-related demand and a still-underappreciated NGS growth engine, with AI-driven order growth expected to reach triple-digits % in FY26 to at least about $50M versus about $25M in FY25, while FY26 revenue is estimated at $446M and the company’s framework to double revenues from FY27-FY31 suggests substantial operating leverage as incremental revenues fall through at gross margins of 75-80%. Despite conservative guidance, the combination of visible demand, multiple adjacent growth paths, and improving profitability implies meaningful upside potential, while the key risks remain slower AI adoption, weaker NGS momentum, and competitive pressure.

Twist Bioscience is viewed negatively because, despite management’s beat-and-raise setup and healthy order trends, the investment case depends heavily on continued execution that is not yet fully de-risked, especially after a strong stock move has already raised expectations. The company still faces meaningful fundamental risk around margin expansion and operating leverage, and if scaling requires more investment sooner than anticipated, the profitability timeline could slip and pressure the valuation multiple even without a collapse in long-term demand. In addition, the stock remains exposed to sector and macro headwinds such as delayed research and development spending, weaker healthcare purchasing, and regulatory friction, while the commentary also highlights that there is no indication NVO will use TWST alongside Claude Science, reducing confidence in near-term incremental demand from that avenue.